A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Gbrcamutation Status

被引：0

作者：

Untch, Michael ^{[1
]}

Fasching, Peter Andreas ^{[2
]}

Mclaurin, Kimmie ^{[3
]}

机构：

[1] Helios Klinikum Berlin Buch, Berlin, Germany

[2] Univ Klinikum Erlangen, Frauenklin, Erlangen, Germany

[3] AstraZeneca, Gaithersburg, MD USA

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

232

引用

页码：11 / 11

页数：1

共 50 条

[1] A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status
McLaurin, Kimmie
Dalvi, Tapashi
Collins, Jenna M.
Nordstrom, Beth L.
McCutcheon, Susan
Bennett, James C.
Murphy, Brian R.
Singhal, Puneet K.
Briceno, Josefa Maria
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status
Jenna M. Collins
Beth L. Nordstrom
Kimmie K. McLaurin
Tapashi B. Dalvi
Susan C. McCutcheon
James C. Bennett
Brian R. Murphy
Puneet K. Singhal
Charles McCrea
Reshma Shinde
Josefa M. Briceno
Oncology and Therapy, 2021, 9 : 575 - 589
[3] A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status
Collins, Jenna M.
Nordstrom, Beth L.
McLaurin, Kimmie K.
Dalvi, Tapashi B.
McCutcheon, Susan C.
Bennett, James C.
Murphy, Brian R.
Singhal, Puneet K.
McCrea, Charles
Shinde, Reshma
Briceno, Josefa M.
ONCOLOGY AND THERAPY, 2021, 9 (02) : 575 - 589
[4] Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania
Miron, Andreea-Iuliana
Anghel, Alexandra-Valentina
Barnonschi, Andrei-Alexandru
Mitre, Ruxandra
Liscu, Horia-Dan
Gainariu, Estera
Patru, Raluca
Coniac, Simona
DIAGNOSTICS, 2023, 13 (11)
[5] The impact of treatment sequence of CDK4/6 inhibitor therapy on Metastatic Breast Cancer treatment outcomes in Real-World practice in U.S
Kimmick, Gretchen
PIlehvari, Asal
You, Wen
Bonilla, Gloribel
Anderson, Roger
CANCER RESEARCH, 2024, 84 (09)
[6] CDK4/6 inhibitors in metastatic breast cancer: An Italian real-world experience
Pantano, F.
Scafetta, R.
Curigliano, G.
Criscitiello, C.
Botticelli, A.
Caputo, R.
D'Auria, G.
Garrone, O.
Gori, S.
Meattini, I.
Minelli, M.
Piras, M.
Rossi, L.
Stucci, L. S.
Tagliaferri, B.
Toss, A.
Vernieri, C.
Vici, P.
Tonini, G.
Santini, D.
ANNALS OF ONCOLOGY, 2023, 34 : S346 - S347
[7] Real-world benefit of CDK4/6 inhibitor and endocrine therapy combination in metastatic breast cancer and correlation with neutropenia
Jenneman, Dakota
Zhong, Xiaojun
Ma, Junjie
Sun, Weihong
Han, Heather
Soliman, Hatem
Loftus, Loretta
Costa, Ricardo
Armaghani, Avan
Soyano, Aixa
Czerniecki, Brian
Lee, M. Catherine
Kiluk, John
Khakpour, Nazanin
Hoover, Susan
Laronga, Christine
Khong, Hung T.
CANCER RESEARCH, 2020, 80 (04)
[8] Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer
Martin, Miguel
Garcia-Saenz, Jose A.
Manso, Luis
Llombart, Antonio
Cassinello, Alejo
Atienza, Manuel
Ringeisen, Francois
Ciruelos, Eva
FUTURE ONCOLOGY, 2020, 16 (33) : 2763 - 2778
[9] Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
Low, Jia Li
Lim, Elaine
Bharwani, Lavina
Wong, Andrea
Wong, Karmen
Ow, Samuel
Lim, Siew Eng
Lee, Matilda
Choo, Joan
Lim, Joline
Chan, Gloria
Walsh, Robert John
Muthu, Vaishnavi
Ngoi, Natalie
Chong, Wanqin
Tan, Sing Huang
Lee, Soo Chin
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
[10] Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real-world evidence in metastatic breast cancer
Liu, Binliang
Hu, Zhe-Yu
Xie, Ning
Liu, Liping
Li, Jing
Yang, Xiaohong
Xiao, Huawu
Zhao, Xuran
Tian, Can
Wu, Hui
Lu, Jun
Gao, Jianxiang
Hu, Xuming
Cao, Min
Shui, Zhengrong
Tang, Yu
Ouyang, Quchang
CANCER INNOVATION, 2024, 3 (06):

← 1 2 3 4 5 →